Tin tức & Cập nhật
Xem bài viết Dược
Xem
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
In the phase III LEAP*-002 study, a combination regimen comprising lenvatinib and pembrolizumab appeared to have similar efficacy and safety as lenvatinib monotherapy as first-line therapy for advanced hepatocellular carcinoma (HCC).
Lenvatinib-pembrolizumab combo fails to spring forward in HCC treatment
19 Oct 2022
Does salt intake truly affect outcomes in HF patients?
A small, single-centre study has suggested that increasing sodium intake does not affect weight or kidney function in patients hospitalized for acute heart failure (HF) who are undergoing aggressive diuretic therapy.
Does salt intake truly affect outcomes in HF patients?
18 Oct 2022
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
The first interim analysis of the phase III IMpower010 trial suggests an overall survival (OS) benefit with atezolizumab compared with best supportive care (BSC) in patients with resected non-small cell lung cancer (NSCLC) with PD-L1* tumour cell expression ≥1 percent.
Does atezolizumab improve OS in patients with resected NSCLC and PD-L1 ≥1 percent?
16 Oct 2022
Anti-TNF continuation after pregnancy prevents relapse in women with IBD
Treatment continuation with antitumour necrosis factor (anti-TNF) after 24 weeks of pregnancy seems to provide benefits in terms of inflammatory bowel disease (IBD) activity and prematurity without affecting neonatal outcomes and serious infections in newborns, reports a study.